| Q73605437 | 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) |
| Q44616568 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
| Q35614631 | 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus |
| Q43818097 | A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection |
| Q33924705 | AIDS across Europe, 1994-98: the EuroSIDA study |
| Q34069806 | Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options |
| Q43818117 | British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy |
| Q61835542 | CIVD, choc septique : Diagnostic biologique et traitements innovants |
| Q34461371 | Clinical indicators of immune restoration following highly active antiretroviral therapy |
| Q38875931 | Co-trimoxazole, cART, and non-AIDS infectious diseases |
| Q35940586 | Colonization by Pneumocystis jirovecii and its role in disease |
| Q28552031 | Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial |
| Q28289603 | Current epidemiology of Pneumocystis pneumonia |
| Q39758104 | Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects |
| Q44794025 | Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. |
| Q45734909 | Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis |
| Q26829541 | Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review |
| Q34236642 | Discovery and clinical development of HIV-1 protease inhibitors |
| Q35693261 | Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated? |
| Q35162307 | Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective |
| Q73903797 | Effect of antiretroviral treatment and prophylaxis for opportunistic infections on survival of patients with AIDS |
| Q28084902 | Effect of cotrimoxazole prophylaxis on malaria occurrence in HIV-infected patients on antiretroviral therapy in sub-Saharan Africa |
| Q54074344 | Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. |
| Q41690799 | Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group |
| Q33894498 | Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy |
| Q35967212 | Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database |
| Q43453614 | Genotyping of Pneumocystis jirovecii isolates from Chinese HIV-infected patients based on nucleotide sequence variations in the internal transcribed spacer regions of rRNA genes |
| Q46472427 | HIV Treatment in Developing Countries |
| Q34967154 | HIV disease and advanced age: an increasing therapeutic challenge |
| Q35059337 | HIV viral suppression in the era of antiretroviral therapy |
| Q35095031 | HIV-1 and bacterial pneumonia in the era of antiretroviral therapy |
| Q58960862 | HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial* |
| Q33910315 | Hit HIV-1 hard, but only when necessary |
| Q34341001 | Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues |
| Q36456559 | Immunological recovery and antiretroviral therapy in HIV-1 infection |
| Q43599627 | Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. |
| Q45735357 | Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. |
| Q36517673 | Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study |
| Q62487989 | Isolates of Pneumocystis jirovecii from Harare show high genotypic similarity to isolates from London at the superoxide dismutase locus |
| Q77856220 | Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era |
| Q41674713 | Molecular detection of pneumocystis jirovecii in patients with respiratory tract infections |
| Q33894511 | Performance measures for guidelines on preventing opportunistic infections in patients infected with human immunodeficiency virus |
| Q34459389 | Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management |
| Q30431684 | Pneumocystis jirovecii pneumonia in Latin America. A public health problem? |
| Q69682534 | Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia |
| Q34004404 | Prophylaxis of Pneumocystis carinii pneumonia: too much of a good thing? |
| Q34122368 | Prophylaxis of opportunistic infections. |
| Q39404140 | Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review |
| Q53514004 | Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection. |
| Q35183728 | Recommendations for the treatment of fungal pneumonias |
| Q44382493 | Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy. |
| Q33969487 | Relationship between mutations in dihydropteroate synthase of Pneumocystis carinii f. sp. hominis isolates in Japan and resistance to sulfonamide therapy. |
| Q33584240 | Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy |
| Q37108386 | TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial |
| Q59243597 | The AIDS epidemic in Lyon: patient characteristics and defining illnesses between 1985 and 2000 |
| Q55363467 | The changing epidemiology of HIV infection: new challenges for HIV palliative care. |
| Q34092112 | The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. |
| Q36504556 | The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa |
| Q34574033 | The pharmacogenomics of HIV therapy. |
| Q35186822 | The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia. |
| Q37180338 | Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) |
| Q34085884 | Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. |
| Q58076934 | Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough? |
| Q35179334 | When to Start Antiretroviral Therapy and What to Start With-- A European Perspective |
| Q73903830 | [New criteria for the prophylaxis of infective diseases in patients infected by HIV] |
| Q73446074 | [Opportunistic infections and highly active antiretroviral therapy] |
| Q74243853 | [Severe bacterial infections after prophylactic suppression of Pneumocystis carinii in HIV infected patients after CD4 lymphocyte recovery] |